Immune monitoring in melanoma and urothelial cancer patients treated with anti-pd-1 immunotherapy and sbrt discloses tumor specific immune signatures - Université de Lille Accéder directement au contenu
Article Dans Une Revue Cancers Année : 2021

Immune monitoring in melanoma and urothelial cancer patients treated with anti-pd-1 immunotherapy and sbrt discloses tumor specific immune signatures

Résumé

(1) Background: Blockade of the PD-1/PD-L1 pathway has revolutionized the oncology field in the last decade. However, the proportion of patients experiencing a durable response is still limited. In the current study, we performed an extensive immune monitoring in patients with stage III/IV melanoma and stage IV UC who received anti-PD-1 immunotherapy with SBRT. (2) Methods: In total 145 blood samples from 38 patients, collected at fixed time points before and during treatment, were phenotyped via high-parameter flow cytometry, luminex assay and UPLC-MS/MS. (3) Results: Baseline systemic immunity in melanoma and UC patients was different with a more prominent myeloid compartment and a higher neutrophil to lymphocyte ratio in UC. Proliferation (Ki67+) of CD8+ T-cells and of the PD-1+/PD-L1+ CD8+ subset at baseline correlated with progression free survival in melanoma. In contrast a higher frequency of PD-1/PD-L1 expressing non-proliferating (Ki67−) CD8+ and CD4+ T-cells before treatment was associated with worse outcome in melanoma. In UC, the expansion of Ki67+ CD8+ T-cells and of the PD-L1+ subset relative to tumor burden correlated with clinical outcome. (4) Conclusion: This study reveals a clearly different immune landscape in melanoma and UC at baseline, which may impact immunotherapy response. Signatures of proliferation in the CD8+ T-cell compartment prior to and early after anti-PD-1 initiation were positively correlated with clinical outcome in both cohorts. PD-1/PD-L1 expression on circulating immune cell subsets seems of clinical relevance in the melanoma cohort.
Fichier principal
Vignette du fichier
Meireson et al.pdf (9.79 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04064764 , version 1 (11-04-2023)

Licence

Identifiants

Citer

Annabel Meireson, Simon J. Tavernier, Sofie van Gassen, Nora Sundahl, Annelies Demeyer, et al.. Immune monitoring in melanoma and urothelial cancer patients treated with anti-pd-1 immunotherapy and sbrt discloses tumor specific immune signatures. Cancers, 2021, Cancers, 13 (11), pp.2630. ⟨10.3390/cancers13112630⟩. ⟨hal-04064764⟩

Collections

UNIV-LILLE
5 Consultations
3 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More